Contact UsInvestorsCareersMediaScienceContact Us
HomePartnershipsWorking With The NHS and other Healthcare OrganisationsCollaborative WorkingCollaborative Working Project between St. George’s University Hospitals NHS Foundation Trust and Pfizer LimitedCollaborative Working Project between St. George’s University Hospitals NHS Foundation Trust and Pfizer Limited
Junior Clinical Fellow (JCF) support to coordinate amyloid clinics and multidisciplinary teams
Background
Cardiac amyloidosis (CA), particularly transthyretin cardiac amyloidosis (ATTR-CM), is increasingly recognized as a significant health concern. Accurate and early diagnosis is critical, especially for hereditary forms like h-ATTR, which require family screening. St. George’s University Hospitals NHS Foundation Trust (SGH) has been a leader in CA care, diagnosing over 400 patients since 2010. However, underdiagnosis persists, particularly among Afro-Caribbean populations with a high prevalence of the V122I mutation. This project addresses diagnostic delays, fragmented care pathways, and health inequities, aligning with NHS Long Term Plan and GIRFT principles.
Project

This collaborative working initiative between SGH and Pfizer Ltd aims to enhance CA care through the appointment of a Junior Clinical Fellow (JCF). The JCF will:

  • Work towards developing and implementing a structured referral algorithm.
  • Coordinate diagnostics and multidisciplinary team (MDT) meetings.
  • Lead on genetic testing and family screening protocols.
  • Build a research-ready patient database.
  • Educate healthcare professionals and support service development.
  • The project also includes a sustainability plan to secure long-term staffing and expand services regionally.
Benefits
Benefits to patients
  • Faster access to diagnostics and treatment.
  • Standardised care pathways and reduced variation.
  • Improved education, empowerment, and quality of life.
  • Enhanced clinical outcomes and quality of life.
  • Greater equity in access, including genetic screening and counselling.

Benefits to the NHS
  • Enhanced collaboration between SGH, National Amyloidosis Centre (NAC), and primary care.
  • Optimised resource use and reduced hospital admissions.
  • Expanded specialist knowledge and data collection.
  • Cost savings through earlier diagnosis and management.

Benefits to Pfizer
  • Suitable patients eligible for approved Pfizer treatments.
  • Insights into service delivery, patient needs, and MDT dynamics.
  • Enhanced understanding of post-discharge care, treatment uptake and potential challenges.
Potential Outcomes
  • Increase the number of patients screened and diagnosed.
  • Reduce time from referral to diagnosis and treatment.
  • Improve patient experience and education.
  • Reduction in health inequities and improved local access.
  • Generate actionable audit data to support future NHS investment.
  • Publish outcomes within six months of project completion.
Proposed Term of the Collaborative Working Project
Planned start date: 1st November 2025.
Planned end date: 31st October 2027.
Resource Allocation
Pfizer Ltd will contribute:
  • Funding:
    • Year 1: £81,357.00
    • Year 2: £78,357.00
  • Human resource
    • Year 1: £6,750.00
    • Year 2: £6,750.00
  • Total transfer of value (2 years): £173,214

Pfizer will provide 50% of the JCF funding and educational budget upfront, with the remaining 50% released after a 12-month evaluation. Total Pfizer transfer of value: £173,214 (financial + the benefit in-kind of the human resources).

SGH will contribute:
  • Funding:
    • Year 1: £43,400.00
    • Year 2: £43,400.00
  • Human resource
    • Year 1: £34,386.00
    • Year 2: £34,386.00
  • Total transfer of value (2 years): £155,572
ResponsibilityHealthcare Organisation Grants

Pfizer is committed to being transparent about the relationships we have with other organisations. 

PartnershipsDonations and Grants

Find out about the donations and grants we make available to support healthcare, scientific research and education.

PP-UNP-GBR-13619 / October 2025
Science Products Responsibility Partnerships Careers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2025 Pfizer Limited. PP-UNP-GBR-13382  / September 2025. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427.  This website is intended for the general public in the UK.